BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-65@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: AstraZeneca — Anifrolumab [Feb 2027]
DESCRIPTION:Phase 3 primary completion: Phase 3 Study of Anifrolumab in Adu
 lt Patients With Active Proliferative Lupus Nephritis.\nSource: https://cl
 inicaltrials.gov/study/NCT05138133\nhttps://catalystbrief.girapphe.com/e/6
 5?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/65?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
